Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allarity Therapeutics, Inc. (Nasdaq: ALLR) on November 29, 2022. The company is incorporated in Delaware and identifies as an emerging growth company. The report addresses a specific corporate governance event regarding the scheduling of the 2023 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The Board of Directors approved a change to the date of the 2023 Annual Meeting of Stockholders. The meeting was rescheduled from January 16, 2023, to January 19, 2023. No changes were made to the record date; stockholders of record as of December 6, 2022, remain entitled to vote.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on business outlook, or new risk factors. The document references a press release (Exhibit 99.1) dated December 1, 2022, which is incorporated by reference for further details on the meeting change.
Key Facts for Investors
- Meeting Date Change: The 2023 Annual Meeting is now scheduled for January 19, 2023.
- Record Date: The record date remains December 6, 2022.
- Proxy Statement: A proxy statement will be filed with the SEC and distributed to stockholders.
- Financial Data: No financial results or metrics are disclosed in this specific filing.